Theriva Biologics
TOVX
18 hedge funds and large institutions have $679K invested in Theriva Biologics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 1 reducing their positions, and 10 closing their positions.
700% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 1
107% more capital invested
Capital invested by funds: $328K → $679K (+$351K)
36.14% more ownership
Funds ownership: 0.32% → 36.46% (+36%)
10% less funds holding
Funds holding: 20 → 18 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$678K |
| 2 |
AC
Armistice Capital
New York
|
+$488K |
| 3 |
Morgan Stanley
New York
|
+$98.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$87.1K |
| 5 |
Two Sigma Investments
New York
|
+$66.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$46K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$33.4K |
| 3 |
Renaissance Technologies
New York
|
-$24.5K |
| 4 |
State Street
Boston,
Massachusetts
|
-$11.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$6.26K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OPTFSNA
26
Old Point Trust & Financial Services N A
Newport News,
Virginia
| – | -$24 | -4 | Closed |
|
27
Wells Fargo
San Francisco,
California
| – | -$24 | -4 | Closed |
|
|
SPIA
28
Steward Partners Investment Advisory
New York
| – | -$3 | -1 | Closed |
|
TOVX Hedge Fund Activity: Q3 2024 in Review
18 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2024, worth a combined $679K — up 107% from $328K a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TOVX and 8 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 8 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $678K. The largest seller was Vanguard Group, exiting entirely with an estimated $46K sold.
- 18 institutional investors held Theriva Biologics (TOVX) as of Q3 2024, down from 20 in Q2 2024.
- Funds reported $679K of Theriva Biologics stock for Q3 2024, up 107% quarter-over-quarter.
- 8 funds opened new Theriva Biologics positions in Q3 2024 and 10 closed out, a net change of -2 holders.
- The largest Theriva Biologics buyer in Q3 2024 was Anson Funds Management, an estimated $678K added.
- The largest Theriva Biologics seller in Q3 2024 was Vanguard Group, an estimated $46K sold.
Based on aggregated 13F filings for Q3 2024.